Introduction
============

Hypopituitarism has been recognized as a rare disorder with an estimated incidence of 4.2 cases per 100,000 per year and an estimated prevalence of 45.5 cases per 100,000 worldwide ([@b1-ijmm-43-01-0155]). It is characterized by the deficiency of one or more of the hormones secreted by the pituitary gland. The disease may result from distinct causes and it may be congenital or acquired. The most common etiology factors for acquired hypopituitarism include pituitary tumors ([@b2-ijmm-43-01-0155]), traumatic brain injury ([@b3-ijmm-43-01-0155]-[@b5-ijmm-43-01-0155]), pituitary irradiation ([@b6-ijmm-43-01-0155]), congenital hypopituitarism (CH), perinatal insults ([@b7-ijmm-43-01-0155]) and genetic mutations ([@b8-ijmm-43-01-0155]). Although the clinical symptoms of this disease are usually unspecific, it may cause life-threatening events and lead to an increased risk of cardiovascular diseases, poor pregnancy potential and infertility for the patients ([@b9-ijmm-43-01-0155],[@b10-ijmm-43-01-0155]).

As a heterogeneous entity with various types of etiology factors, mutations in the genes encoding a number of hypothalamo-pituitary transcription factors, including HESX homeobox 1 (HESX1), LIM homeobox 1 (LHX1), PROP paired-like homeobox 1 (PROP1), and POU class 1 homeobox 1 (POU1F1) may lead to CH; however, only 10% of cases are estimated to be caused by genetic factors ([@b11-ijmm-43-01-0155]). Prenatal or birth trauma and/or asphyxia and specific types of midline defect syndromes may additionally lead to CH ([@b12-ijmm-43-01-0155]); however, their association with CH are usually hard to determine. The underlying mechanisms for the clinical symptoms of patients with CH are due to the deficiency in pituitary hormones, including the growth hormone, adrenocorticotropin (ACTH), prolactin (PRL), thyroid stimulating hormone (TSH), luteinising hormone (LH) and follicle-stimulating hormone (FSH) ([@b13-ijmm-43-01-0155]). These deficiencies result in recurrent hypoglycemia and acute adrenal insufficiency with impairments of growth and neurodevelopment ([@b13-ijmm-43-01-0155]). Furthermore, due to the lack of gonadotropin hormones, spermatogenesis and/or testicular development are abnormal, resulting in infertility for male patients. In females, successful pregnancy is rare, as hypopituitarism is associated with an increased risk of pregnancy complications, including abortion, anemia, pregnancy-induced hypertension, placental abruption, premature birth and postpartum hemorrhage ([@b14-ijmm-43-01-0155]). In the clinical setting, lifelong hormone replacement treatment (HRT) is applied to patients with CH with corticosteroids, levothyroxine, sex hormones and growth hormones; however, the treatments may only partially recover the abnormal development of patients and therefore they remain at high risk of infertility and mortality ([@b15-ijmm-43-01-0155]-[@b17-ijmm-43-01-0155]). Therefore, the underlying molecular mechanisms for the pathogenesis of CH require further examination.

DNA methylation is a crucial epigenetic modification that influences the structure of the genome and regulates subsequent gene transcription activities ([@b18-ijmm-43-01-0155]). Previous studies of targeted gene methylation demonstrated the significant associations between DNA methylation and hormone exposure in early-life, particularly in hormonally-mediated sexual differentiation ([@b19-ijmm-43-01-0155],[@b20-ijmm-43-01-0155]). As DNA methylation status may affect gene expression in response to hormones during the lifespan ([@b20-ijmm-43-01-0155]), it is possible that DNA methylation may be modified in patients with CH with hormone deficiency, and it may be involved in the development and progression of the disease. Therefore, the epigenome-wide methylation status of the whole blood DNA was detected in patients with CH, in order to identify genes that may be aberrantly methylated in patients with CH compared with control subjects. The present results may provide further insight into the pathogenesis of the disease and may provide novel therapeutic targets for CH treatment and biomarkers for diagnosis.

Materials and methods
=====================

Participant recruitment
-----------------------

The discovery set included 12 male patients with CH and 12 male healthy controls matched for age (±3 years) and body-mass index (±1 kg/m^2^). The participants were recruited at the Ruijin Hospital North (Shanghai, China) between November 2015 and May 2016. Eligible patients were clinically diagnosed with hypopituitarism based on clinical history, symptoms, biochemical and brain magnetic resonance imaging (MRI) tests. Patients with pituitary tumors, traumatic brain injury, pituitary irradiation or a clear diction of dystocia history were excluded. All CH patients had been diagnosed with panhypopituitarism with multiple pituitary hormone deficiency at a young age (\~6-12 years old). The MRI scan of all the patients with CH suggested a presence of a transected or interrupted hypothalamic-pituitary stalk or pituitary hypoplasia ([@b21-ijmm-43-01-0155]). The patients had received routine cortisone and levothyroxine treatment; however, had not yet received the human chorionic gonadotrophin treatment at the time of recruitment. Controls were selected from local residents receiving annual physical examination, were free of acute or chronic diseases (including diabetes, cancer and cardiovascular diseases), and had no symptom of growth and developmental abnormalities. The validation set included another 40 male patients with CH and 40 age-matched male controls. The recruitment of the validation set followed the same protocols as described for the discovery set, and was conducted between June 2016 and July 2017. Written informed consent was obtained from all the participants, and the study was approved by the Institutional Review Board of Ruijin Hospital North.

Endocrinological hormone tests
------------------------------

The serum hormonal levels were determined to evaluate the hormone secretion activity of the pituitary gland during the drug withdrawal period, using commercial radioimmunoassay kits in the clinic. The blood levels of free thyroxine 3, free thyroxine 4 (FT4), TSH, cortisol, ACTH, LH, FSH, PRL, progesterone (PROG) and testosterone were determined with Beckman DX I800 instruments (Beckman Coulter, Inc., Brea, CA, USA), according to the manufacturer's protocol in the clinical testing lab.

Genome-wide DNA methylation level analysis
------------------------------------------

In total, 5 ml blood was provided by each participant during their drug withdrawal period and the genomic DNA was isolated using the QIAamp DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany). Following quality assessment, bisulfite conversion of the genomic DNA was performed using the Zymo EZ DNA Methylation kit (Zymo Research Corp., Irvine, CA, USA). DNA methylation levels of blood were quantified with the Human Methylation450K BeadArray (Illumina, Inc., San Diego, CA, USA) following the manufacturer's protocol, and the samples of cases and controls were processed simultaneously. The methylation level of a specific CpG site was quantified as a β value ranging from 0 (no methylation) to 1 (full methylation). The raw DNA methylation β values were normalized using the Subset-quantile Within Array Normalization method ([@b22-ijmm-43-01-0155]) with the minfi Bioconductor (version 1.26.2) package ([www.bioconductor.org](http://www.bioconductor.org)). Probes with detection P\>0.01 and/or covering potential single nucleotide polymorphism (SNP) sites were excluded from analysis. Student's t-test was performed to identify the significantly methylated CpG loci between the patients with CH and controls. The top candidate probes were selected based on an adjusted P-value using the Benjamini-Hochberg False Discovery Rate (FDR) procedure with adjusted P\<0.05 and β-difference \>0.14 ([@b23-ijmm-43-01-0155]). The DNA methylation data are available at the NCBI Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>) under accession no. GSE107737.

Pathway enrichment analysis of the differentially methylated genes was performed with the publicly available tool Protein Analysis Through Evolutionary Relationships (PANTHER; <http://www.pantherdb.org/>) that provides access to various gene set libraries ([@b24-ijmm-43-01-0155]). A pathway was considered as significantly enriched if the FDR P-value was \<0.05.

Pyrosequencing analysis
-----------------------

The pyrosequencing method was applied in order to determine the methylation level of candidate CpG sites in the validation set. The bisulfite conversion and cleanup of DNA samples was performed with the EpiTect Fast Bisulfite Conversion kit (Qiagen,GmbH). Fragments covering the target sites were amplified from the bisulfite converted genomic DNA with the biotinylated forward and normal reverse primers, which were designed with PyroMark Assay Design Software (version 2.0; Qiagen, GmbH). The biotinylated polymerase chain reaction (PCR) was performed with EpiTap™ HS polymerase (Takara Biotechnology Co., Ltd., Dalian, China) and the thermocycling conditions were as follows: 98°C for 10 sec, 55°C for 30 sec, 72°C for 30 sec with 35 cycles followed by 72°C for 45 sec and 4°C for hold. The amplicon product was purified and made into single-stranded, which was used as the template in the pyrosequencing reaction. The pyrosequencing was conducted using the Pyro Mark Q24 Advanced (Qiagen, GmbH), according to the manufacturer's protocol, with the specific sequencing primers (cg01606027, forward PCR primer 5′-TTT TGG TTA TTT GGA TAT GTT TTT TGT GAT-3′, reverse PCR primer 5′-TCA ACC AAA CCA ACT AAT CCC TAA TA-3′, and pyrosequencing primer 5′-GTA AGG AAA TGA TAA TTG TGA A-3′; cg03594078, forward PCR primer 5′-TGT GTA AAT ATT TAA TGG TAG TAA GTG TAG -3′, reverse PCR primer 5′-AAT TTA CTA AAT CCT ACC CCC AAA A-3′ and the pyrosequencing primer 5′-AAT TTT TTG TTT TTT TAG GAA TT-3′). The PyroMark CpG Software 1.0 (Qiagen, GmbH) was used to calculate the CpG methylation levels based on the height of the T and C peaks at the methylation site with the formula C/(C + T) ×100.

Reverse transcription-quantitative (RT-q)PCR in whole blood cells
-----------------------------------------------------------------

The white blood cells of the participants in the training cohort were purified from whole blood collected in the EDTA sodium tubes, by centrifugation at 2,000 x g for 15 min at room temperature. The white blood cells were lysed with the TRIzol^®^ reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the total RNA was extracted with the Direct-zol RNA kit (Zymo Research, Corp.). A total of 500 ng total RNA were used to synthesize the cDNA using the PrimeScript 1st strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd.) and incubated at 30°C for 10 min, 42°C for 30 min followed by 70°C for 15 min. The qPCR reaction was performed with the SYBR^®^ Premix Ex Taq II kit (Takara Biotechnology Co., Ltd.). LIM domain kinase 2 (LIMK2) and piwi-like RNA-mediated gene silencing 2 (PIWIL2), The primers were: LIM kinase 2 (LIMK2), forward 5′-GGA TTC CCT CAC CAA CTG GTA-3′ and reverse 5′-AGC CAC CAT AAA AGG CCC TG-3′; piwi-like RNA-mediated gene silencing 2 (PIWIL2), forward 5′-AGC AGG TGG TAT CAG CAG AGA-3′ and reverse 5′-TGT ATT TTG ACG AGG TTC AGT CC-3′; and GAPDH, forward 5′-AAG GTG AAG GTC GGA-3′ and reverse 5′-AAT GAA GGG GTC ATT GAT GG-3′. qPCR was performed at 95°C for 30 sec followed by 95°C for 5 sec and 60°C for 30 sec with 40 cycles. Relative expression of the genes was calculated relative to the mean expression level of LIMK2 and PIWIL2 in the control group normalized by GAPDH with the 2^-ΔΔCq^ method ([@b25-ijmm-43-01-0155]).

Statistical analysis
--------------------

Age, weight, height and body mass index (BMI) of the participants are presented as mean ± standard deviation and the differences between the groups were analyzed with the Student's t-test. The hormone levels of the participants were presented as median level in together with the lowest to highest range of the hormone, and the differences between the groups were evaluated with the Mann-Whitney test. Differences for the methylation levels of the CpG sites in pyrosequencing analysis and the relative expression of the genes between the groups were evaluated with the Student's t-test. The receiver-operating characteristic (ROC) curve analysis and the corresponding area under the curve (AUC) were calculated to determine the diagnosis values for the methylation levels of the candidate CpG sites. All analyses were performed with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Baseline characteristics of the participants in the discovery set
-----------------------------------------------------------------

To compare the genome-wide methylation levels of the whole blood DNA, first, 12 patients with CH and 12 age-matched controls (±3 years) were recruited as the discovery set. The basic clinical characteristics of the participants are presented in [Table I](#tI-ijmm-43-01-0155){ref-type="table"}. The mean age for the patients with CH was 21.58±2.71 years and 24.00±3.67 years for the controls (P=0.081). All patients with CH had received stan-dardized cortisone and levothyroxine therapy at the time of enrollment with the median treatment time of 6 years (range 2-10 years), and none of them had received the human chorionic gonadotrophin treatment. All patients had a symptom of oligospermia or azoospermia at the time of recruitment with the Tanner stage between G1 to G3 ([Table I](#tI-ijmm-43-01-0155){ref-type="table"}). No significant difference was identified between the patients with CH and controls for height, weight and body mass index ([Table I](#tI-ijmm-43-01-0155){ref-type="table"}). Compared with the controls, the patients with CH had significantly lower levels of the hormones secreted by the pituitary gland. In addition, significantly lower FT4, cortisol and ACTH levels were observed in the patients with CH compared with the controls ([Table I](#tI-ijmm-43-01-0155){ref-type="table"}). Furthermore, the hormones associated with gonadotropic function, LH, FSH, PROG and TESTO, were additionally at lower levels in the patients with CH compared with the controls ([Table I](#tI-ijmm-43-01-0155){ref-type="table"}).

Genome-wide methylation analysis of whole blood DNA in CH patients
------------------------------------------------------------------

Using the Human Methylation450K BeadArray, the CpG methylation levels of the whole blood DNA in patients with CH and controls were determined. The Manhattan plot demonstrated the CpG sites on each chromosome and their corresponding unadjusted P-values for the differences of meth-ylation levels between patients with CH and the controls ([Fig. 1](#f1-ijmm-43-01-0155){ref-type="fig"}). The selection criteria for the candidate CpG sites are presented in [Fig. 2](#f2-ijmm-43-01-0155){ref-type="fig"}. Following the epigenome-wide methylation analysis of the discovery set, 58,128 differentially methylated probes (DMPs) were identified between the patients with CH and the controls (unadjusted P-value \<0.05). Of these, 3,225 DMPs had an FDR adjusted P\<0.05 and 64 probes had a β-difference \>0.14. Subsequent to excluding probes covering potential SNP sites, 51 significantly aberrant methylated CpG sites were selected for further analysis ([Fig. 3](#f3-ijmm-43-01-0155){ref-type="fig"}). Of these, 50 sites were hypermethylated, whereas, only one CpG site, cg18706028, was hypomethylated in patients with CH ([Fig. 3](#f3-ijmm-43-01-0155){ref-type="fig"}). These 51 DMPs were clustered into five regions according to gene annotation, including 10 DMPs located the in TSS1500Ind, one DMP in TSS200Ind, 27 DMPs located on gene body, three in the 5′-untranslated region (UTR), one in the 3′-UTR region of the gene, and the other 10 DMPs located in the intergenic region ([Table II](#tII-ijmm-43-01-0155){ref-type="table"}).

Gene set enrichment analysis of the aberrant methylated genes
-------------------------------------------------------------

To provide further insights into the biological processes associated with the aberrant methylated genes in the patients with CH, a gene set enrichment analysis was conducted for these genes using the PANTHER classification system. The 41 candidate genes with significant DMPs were included in the analyses ([Table II](#tII-ijmm-43-01-0155){ref-type="table"}). The results demonstrated that the genes were significantly enriched in the biological processes of 'metabolic process', 'cellular process', 'localization', 'response to stimulus', 'immune system process' and 'reproduction' ([Fig. 4A](#f4-ijmm-43-01-0155){ref-type="fig"}). The significantly enriched molecular functions of these genes were 'catalytic activity', 'binding', 'receptor' and 'transporter activity' ([Fig. 4B](#f4-ijmm-43-01-0155){ref-type="fig"}). The top enriched protein classes were 'transferase', 'nucleic acid binding', 'cytoskeletal protein' and 'receptor' ([Fig. 4C](#f4-ijmm-43-01-0155){ref-type="fig"}), while the top ranked cellular components were 'cell part' and 'organelle' ([Fig. 4D](#f4-ijmm-43-01-0155){ref-type="fig"}).

LIMK2 and PIWIL2 are hypermethylated in patients with CH
--------------------------------------------------------

CH in male patients is typically associated with decreased spermatogenesis and testicle development latency ([@b26-ijmm-43-01-0155]). The methylation analysis demonstrated that the genes LIMK2 and PIWIL2, which have vital roles in the reproductive system development, were hypermethylated in the TSS1500Ind region ([Table II](#tII-ijmm-43-01-0155){ref-type="table"}). As the hypermethylation of CpG sites in the promoter may reduce the transcription activities of the target genes, it was hypothesized that the aberrant methylation of these two genes may be involved in the infertility of the male patients with CH. With the pyrosequencing methods, the hypermethylated levels of cg01606027 on LIMK2 and cg03594078 on PIWIL2 of the CH patients in the discovery cohort were validated and it was identified that the methylation level of the two CpG sites was significantly increased in patients with CH (P\<0.001 for the two sites; [Fig. 5A](#f5-ijmm-43-01-0155){ref-type="fig"}). In addition, the mRNA expression levels of LIMK2 and PIWIL2 in white blood cells were significantly decreased in the patients with CH compared with the normal controls, as detected by RT-qPCR analysis ([Fig. 5B](#f5-ijmm-43-01-0155){ref-type="fig"}). The methylation levels of these two loci were further determined in another validation set with 40 pairs of patients with CH and controls. The baseline characteristics of the validation set are presented in [Table III](#tIII-ijmm-43-01-0155){ref-type="table"}. No significant difference was observed for the basic characteristics in patients with CH and controls, whereas, the blood levels of TSH, cortisol, ACTH, LH, FSH, PRL and TESTO were significantly lower in the patients with CH compared with controls ([Table III](#tIII-ijmm-43-01-0155){ref-type="table"}). Compared with the controls, the methylation of the cg01606027 on LIMK2 and cg03594078 on PIWIL2 was increased in the patients with CH (P\<0.001 for the two sites; [Fig. 5C](#f5-ijmm-43-01-0155){ref-type="fig"}). To estimate the potential diagnostic power of these two methylated CpG sites with regards to differentiating CH samples from controls, the predictive performance of the methylation levels of the two CpG sites for CH disease was examined with the ROC test in the validation cohort. The AUC was 0.706 \[95% confidence interval (CI), 0.591-0.821; [Fig. 6A](#f6-ijmm-43-01-0155){ref-type="fig"}\] for cg01606027 and 0.716 (95% CI, 0.601-0.830; [Fig. 6B](#f6-ijmm-43-01-0155){ref-type="fig"}) for cg03594078, suggesting that the two loci may hold promise in CH disease diagnosis.

Discussion
==========

In the present study, the genome-wide DNA methylation levels in the peripheral blood of male patients with CH were determined and compared with age-matched controls. A total of 51 DMPs, that may influence gene expression levels involved in CH development and progression, were identified. Pathway enrichment analysis of the hypermethylated and hypomethylated DMP-associated genes demonstrated that these were involved in 'metabolic process', 'immune system process' and 'reproduction'. In addition, two hypermethylated CpG loci located on the promoter regions of LIMK2 and PIWIL2, which are closely associated with testiculal development and spermatogenesis, were observed in the patients with CH. These results suggested that epigenetic alterations may contribute to the pathogenesis of CH, and may provide novel therapeutic targets in the future. Furthermore, the methylation levels of the two loci had moderate predictive abilities in patients with CH, suggesting that these may serve as potential diagnostic or therapeutic markers for CH in the future.

CH is a heterogeneous disease with complex causes, which may be acquired or are idiopathic ([@b27-ijmm-43-01-0155],[@b28-ijmm-43-01-0155]). Previous studies observed that the most common mutated genes in patients with CH are PROP1, POU1F1, OTX2, HESX1, LHX3, GLI2, CDON, TGIF, SHH and LHX412; however, the prevalence of mutations on these genes was low ([@b29-ijmm-43-01-0155],[@b30-ijmm-43-01-0155]). Prenatal and birth trauma or asphyxia may additionally lead to CH; however, their associations with CH are not yet well established. Therefore, the exact pathogenesis of CH remains unclear.

DNA methylation, which is the addition of a methyl group to the cytosine in a CpG dinucleotide, has vital roles in development and cellular differentiation. Aberrant methylation of genes has been demonstrated to contribute to the development and progression of various diseases. Due to the severe deficiency of the hormones secreted by the pituitary gland, HRT is an effective treatment method for patients with CH; however, they still present with increased risk for hypoglycemia, cardiovascular diseases, microphallus, infertility and hepatitis ([@b12-ijmm-43-01-0155]). Previous studies demonstrated that the hormone deficiency is significantly associated with DNA methylation levels ([@b31-ijmm-43-01-0155],[@b32-ijmm-43-01-0155]). Gonadotropin deficiency results in lower levels of testosterone in male patients with CH ([@b33-ijmm-43-01-0155]). With a mouse embryonic neural stem cell (eNSC) model, Bramble *et al* ([@b34-ijmm-43-01-0155]) demonstrated that transcripts in response to testosterone-propionate (TP) treatment are enriched in genes that affect histone modification and DNA methylation. The TP treatment results in a global decrease in 5-methylcytosine abundance in the genomic DNA, and the DNA hypomethylation is maintained in the daughter cell linages of eNSCs post-exposure ([@b34-ijmm-43-01-0155]). These results suggested that testosterone deficiency in early life may lead to the aberrant hypermethylation of genes, which contributes to the pathogenesis of neural diseases ([@b34-ijmm-43-01-0155]). In addition, DNA methylation levels additionally influence the response to hormone treatment in the clinic. Ouni *et al* ([@b35-ijmm-43-01-0155]) demonstrated that the P2 promoter of the IGF1 gene mediated the responsiveness to growth hormone in short children. Therefore, aberrant epigenetic gene modulation may contribute to the pathogenesis of CH and additionally influence the responsiveness of patients to hormone treatment.

LIMK2 belongs to the serine LIM kinase family (including LIMK1 and LIMK2) and it serves as a regulator of actin dynamics ([@b36-ijmm-43-01-0155]). Previous studies demonstrated that LIMK2 has important roles in cell movement, division and structure formation ([@b37-ijmm-43-01-0155],[@b38-ijmm-43-01-0155]). A previous study observed that LIMK2 stimulates pathologic cancer cell division by regulating actin filaments ([@b39-ijmm-43-01-0155]). In addition, LIMK2 is not only involved in mitosis; however, additionally meiosis, and LIMK2 activity is essential for microtubule center organization and distribution in mouse oocyte meiosis ([@b40-ijmm-43-01-0155],[@b41-ijmm-43-01-0155]). Using a mouse knockout model, Takahashi *et al* ([@b42-ijmm-43-01-0155]) identified that LIMK2^−/−^ mice did not demonstrated embryonic lethality or any phenotypic abnormalities in the postnatal growth and development, except for the lack of spermatogenesis in the testis. Compared with the wide-type mice, LIMK2^−/−^ mice were smaller in size and had partial degeneration of spermatogenic cells in the seminiferous tubules ([@b42-ijmm-43-01-0155]). The viability of the LIMK2^−/−^ spermatogenic cells was significantly diminished under stress conditions and the potential for germ cells to differentiate in a regenerative state was additionally impaired in the LIMK2^−/−^ testis ([@b42-ijmm-43-01-0155]). These results suggested that LIMK2 is critical for the proper progression of spermatogenesis. The present study demonstrated that LIMK2 was hypermethylated and downregulated in the white blood cells of patients with CH compared with the controls, which may partially explain the impaired spermatogenic ability of the patients. LIMK2 may serve as a potential therapeutic target for CH and treatment with testosterone may decrease the methylation of LIMK2 in testicular germ cells. In addition, the methylation levels of LIMK2 may influence the outcome of HRT in the clinic; however, these considerations require further examination in future studies.

PIWIL2, additionally termed MILI, belongs to the PIWI family, a group of argonaute proteins that interact with a class of small piwi-interacting (pi)RNAs, specifically expressed in the testes during spermatogenesis ([@b43-ijmm-43-01-0155]). In the mammalian testes, PIWIL2 is involved in the early phases of spermatogenesis, maintaining genome stability by regulating the retrotranspo-sons through DNA methylation silencing in germline cells ([@b44-ijmm-43-01-0155]). PIWIL2 is required for germline stem cell self-renewal ([@b45-ijmm-43-01-0155]), and PIWIL2 deficiency leads to increased transposon expression, and defects in meiosis and germ cell survival ([@b46-ijmm-43-01-0155]). Heyn *et al* ([@b47-ijmm-43-01-0155]) observed that PIWIL2 was hypermethylated in the semen DNA of infertile males, which resulted in the defective production of piRNAs and the hypomethylation of the LINW-1 repetitive sequence. Friemel *et al* ([@b48-ijmm-43-01-0155]) identified that the PIWIL2 was hypermethylated in in the peripheral blood DNA of patients with idiopathic male infertility compared with control males, which is consistent with the results of the present study. These results suggested that DNA methylation of PIWIL2 may regulate gene expression in spermatogenesis and result in abnormal sperm cell development, which may partially contribute to the infertility disorders of male patients with CH in the clinic.

Besides these two loci, CpG sites located in other genes, including hypoxia-inducible factor (HIF)-3α and regulatory-associated protein of mammalian target of rapamycin (mTOR) complex 1 (RPTOR), were additionally noted in the present study; however, their roles in CH development and progression remain unknown. Hypermethylation of HIF-3α has been observed in children with obesity, and a positive association between BMI and DNA methylation level of HIF-3α was identified in a previous study ([@b49-ijmm-43-01-0155]). HIF-3α is highly expressed in adipocytes and has vital roles in adipogenesis ([@b50-ijmm-43-01-0155]). Pfeiffer *et al* ([@b51-ijmm-43-01-0155]) demonstrated that the methylation levels of CpG site cg22891070, which was hypermethylated in patients with CH, was significantly higher in visceral adipose tissue (VAT) compared with subcutaneous adipose tissue (SAT), and cg22891070 methylation levels were significantly correlated with BMI, and abdominal SAT and VAT area. Therefore, aberrant HIF-3α methylation may contribute to adipose tissue dysfunction, which may lead to the increased risk of obesity-associated diseases in patients with CH. Two CpG sites (cg27511181 and cg06418238) were identified to be hypermethylated in the gene body of RPTOR, which is an important scaffolding protein that recruits the mTOR substrates to rapamycin-senstitive mTOR complex 1 (mTORC1) ([@b52-ijmm-43-01-0155]). RPTOR is required for the suppressive function of regulatory T cells ([@b53-ijmm-43-01-0155]). Tang *et al* ([@b54-ijmm-43-01-0155]) demonstrated that the CpG site cg06418238 was hypomethylated in the peripheral blood DNA of patients with breast cancer compared with controls. However, the role of RPTOR and its hypermethylation in the development and progression of CH remain unclear. In the future, novel identified epigenetically regulated genes and their roles in CH development and progression require further investigation, which may provide further insight for the mechanisms for the pathogenesis of CH.

There were a number of limitations of the present study. The sample size in the discovery set was relatively small. Other CpG sites that may be aberrantly methylated in patients with CH may not have been identified due to the statistical power limitations. The methylation status of the genomic DNA was derived from the whole blood, and its consistence with the DNA methylation levels in the target cells of the pituitary gland or testes are largely unknown. Whether LIMK2 and PIWIL2 were hypermethylated in sperm cells and their roles in the infertility of patients with CH require examination in the future. The mechanisms for the aberrant methylation levels of the target genes remain unknown. Whether the hypermethylation or hypomethylation of the CpG sites was caused by perinatal damage or hormone deficiency, and the molecular mechanisms for the epigenetic regulation of these genes under stress require further investigation in future studies. The effect of HRT in the epigenetic regulation of the aberrantly methylated genes in patients with CH and whether the methylated loci may regulate the outcome of HRT requires further study.

In conclusion, the present study determined the genome-wide DNA methylation levels of the peripheral whole blood DNA in male patients with CH and demonstrated that 51 CpG sites were significantly hypermethylated or hypomethylated in patients with CH compared with normal controls. Two CpG sites cg01606027 and cg03594078 located at the coding region of the genes LIMK2 and PIWIL2, that are essential for spermatogenesis, were hypermethylated, which may contribute to azoospermia or oligozoospermia in male patients with CH. These results suggested that the aberrant epigenetic regulated genes may contribute to the pathogenesis of CH, and that they may serve as novel therapeutic targets or diagnosis biomarkers for CH in the future.
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![Hierarchical clustering analysis for the 51 significantly differentially methylated CpG sites between the patients with congenital hypopituitarism and the controls. Red denotes hypermethylated levels and blue color hypomethylated levels.](IJMM-43-01-0155-g02){#f3-ijmm-43-01-0155}

![Gene set enrichment analyses for the aberrantly methylated genes between the patients with congenital hypopituitarism and the controls. (A) Biological process. (B) Molecular function. (C) Protein class. (D) Cellular component. The terms were sorted according to the -log (FDR P-value). FDR, false discovery rate; GO, gene ontology.](IJMM-43-01-0155-g03){#f4-ijmm-43-01-0155}

![CpG sites on LIMK2 (cg01606027) and PIWIL2 (cg03594078) are hypermethylated and the expression levels of LIMK2 and PIWIL2 are reduced in patients with CH. (A) Pyrosequencing of CpG sites cg01606027 on LIMK2 and cg03594078 on PIWIL2 suggested that the two sites were hypermethylated in patients with CH compared with controls in the discovery set (n=12). (B) Reverse transcription-quantitative polymerase chain reaction results suggested that the mRNA expression levels of LIMK2 and PIWIL2 were significantly reduced in patients with CH compared with normal controls in the discovery set (n=12). Data are presented as mean ± standard error of the mean. (C) Pyrosequencing suggested that the methylation levels of CpG sites cg01606027 on LIMK2 and cg03594078 on PIWIL2 were increased in patients with CH compared with controls in the validation set (n=40). LIMK2, LIM domain kinase 2; PIWIL2, piwi-like RNA-mediated gene silencing 2; CH, congenital hypopituitarism.](IJMM-43-01-0155-g04){#f5-ijmm-43-01-0155}

![ROC curves for the diagnosis of patients with congenital hypopituitarism. ROC curves according to the methylation levels of (A) cg01606027 on LIM domain kinase 2 and (B) cg03594078 on piwi-like RNA-mediated gene silencing 2, in the validation set. The blue line represents the binormal smoothed ROC curve for each CpG site. ROC, receiver-operating characteristic; AUC, area under the curve; CI, confidence interval.](IJMM-43-01-0155-g05){#f6-ijmm-43-01-0155}

###### 

Characteristics of the paired patients congenital with hypopituitarism and controls in the discovery set.

  Characteristics          Congenital hypopituitarism, n=12   Controls, n=12        P-value
  ------------------------ ---------------------------------- --------------------- ---------
  Basic information                                                                 
   Age, years              21.58±2.71                         24.00±3.67            0.081
   Height, cm              169.0±8.72                         173.0±5.17            0.185
   Weight, kg              65.13±16.94                        67.75±3.93            0.606
   BMI, kg/m^2^            22.42±3.95                         22.70±1.92            0.827
   Tanner stage            G1/G2/G3 (3/6/3)                   \-                    \-
  Thyroid function                                                                  
   FT3, pmol/l             3.70 (2.69-6.34)                   4.22 (3.51-5.06)      0.434
   FT4, pmol/l             9.67 (6.86-17.19)                  13.52 (11.67-17.08)   0.018
   TSH, *µ*IU/l            0.69 (0.00-5.94)                   1.80 (0.56-2.76)      0.369
  Corticotropic function                                                            
   Cortisol, *µ*g/dl       0.465 (0.01-5.55)                  12.41 (7.10-21.00)    \<0.001
   ACTH, pg/ml             9.09 (5.27-10.96)                  42.00 (20.00-55.00)   \<0.001
  Gonadotropic function                                                             
   LH, mIU/l               0.11 (0.01-1.26)                   4.05 (1.47-5.29)      \<0.001
   FSH, *µ*IU/ml           0.18 (0.02-1.70)                   4.97 (1.80-7.98)      \<0.001
   PRL, ng/ml              16.81 (2.21-49.13)                 8.58 (4.27-11.62)     0.065
   E2, pg/ml               20.00 (20.00-28.60)                26.46 (20.00-35.40)   0.087
   PROG, ng/ml             0.10 (0.10-0.20)                   0.12 (0.10-0.79)      0.017
   TESTO, ng/ml            0.10 (0.10-2.00)                   4.75 (2.25-7.01)      \<0.001

The data for basic information are presented as the mean ± standard deviation. All other data are presented as the median (range). ACTH, adrenocorticotropic hormone; BMI, body mass index; FT3, free thyroxine 3; FT4, free thyroxine 4; TSH, thyroid stimulating hormone; PRL, prolactin; PROG, progesterone; TESTO, testosterone; LH, luteinising hormone; FSH, follicle-stimulating hormone.

###### 

Differentially methylated positions in the peripheral blood DNA of 12 paired patients with congenital hypopituitarism and controls in the discovery set.

  Gene/CpG region   Gene symbol   CpG site     P-value    FDR P-value   β-difference[a](#tfn2-ijmm-43-01-0155){ref-type="table-fn"}   Chr   Region
  ----------------- ------------- ------------ ---------- ------------- ------------------------------------------------------------- ----- ---------
  TSS1500Ind        C11orf41      cg08939373   0.0002     0.0391        −0.1453                                                       11    \-
                    GPR77         cg15361750   \<0.0001   0.0170        −0.1517                                                       19    \-
                    LIMK2         cg01606027   0.0001     0.0277        −0.1715                                                       22    N_Shore
                    NEIL3         cg14022913   0.0001     0.0255        −0.1429                                                       4     N_Shore
                    SLC27A3       cg00421624   \<0.0001   0.0052        −0.1515                                                       1     N_Shore
                    PRR4          cg23256579   \<0.0001   0.0011        −0.1650                                                       12    \-
                    GLRX          cg10949007   0.0001     0.0281        −0.2245                                                       5     \-
                    HNRPLL        cg18107006   \<0.0001   0.0043        −0.1682                                                       2     S_Shore
                    PIWIL2        cg03594078   \<0.0001   0.0132        −0.1414                                                       8     N_Shore
  TSS200Ind         HIF3A         cg22891070   0.0001     0.0227        −0.1683                                                       19    S_Shore
  GENEBODY          AGA           cg09976051   0.0001     0.0264        −0.1792                                                       4     N_Shore
                    C20orf3       cg20661985   0.0001     0.0267        −0.1460                                                       20    N_Shelf
                    CCKBR         cg18706028   0.0001     0.0305        0.1487                                                        11    Island
                    DOT1L         cg04173586   0.0001     0.0212        −0.1632                                                       19    S_Shore
                    ECT2          cg10028625   0.0003     0.0455        −0.1628                                                       3     \-
                    FLJ13197      cg21199922   \<0.0001   0.0039        −0.1433                                                       4     \-
                    KCNK5         cg05255811   \<0.0001   0.0113        −0.1495                                                       6     \-
                    N4BP1         cg27319917   \<0.0001   0.0041        −0.1410                                                       16    \-
                    NKG7          cg10126923   \<0.0001   0.0013        −0.1487                                                       19    S_Shelf
                    PLEK          cg13468685   \<0.0001   0.0045        −0.1444                                                       2     \-
                    PLEKHM1P      cg06064179   0.0001     0.0335        −0.1433                                                       17    N_Shelf
                    PRPSAP2       cg14817867   \<0.0001   0.0096        −0.1473                                                       17    \-
                    RASA3         cg10800346   0.0001     0.0221        −0.1600                                                       13    \-
                    REV3L         cg09365147   \<0.0001   0.0156        −0.1423                                                       6     \-
                    TAF1B         cg25588844   \<0.0001   0.0021        −0.1572                                                       2     \-
                    THOC7         cg22134162   \<0.0001   0.0067        −0.1404                                                       3     \-
                    TRIM35        cg05755408   \<0.0001   0.0045        −0.1580                                                       8     \-
                    VIM           cg26063719   \<0.0001   0.0033        −0.1440                                                       10    S_Shore
                    WIPI1         cg25161129   \<0.0001   0.0123        −0.1550                                                       17    N_Shore
                    FGGY          cg10220544   0.0003     0.0482        −0.1429                                                       1     \-
                    KDM1A         cg25199552   0.0001     0.0333        −0.1476                                                       1     S_Shelf
                    RPTOR         cg27511181   \<0.0001   0.0035        −0.1568                                                       17    \-
                    RPTOR         cg06418238   \<0.0001   0.0050        −0.1449                                                       17    \-
                    THADA         cg22033476   \<0.0001   0.0198        −0.1500                                                       2     \-
                    CTSC          cg08522340   \<0.0001   0.0038        −0.1503                                                       11    N_Shelf
                    DPH5          cg04205769   0.0001     0.0333        −0.1481                                                       1     N_Shelf
                    PROM1         cg17791799   0.0003     0.0456        −0.1434                                                       4     \-
  UTR5Ind           AGPAT4        cg02627227   \<0.0001   0.0033        −0.1600                                                       6     \-
                    CPNE3         cg12162100   0.0003     0.0493        −0.1583                                                       8     S_Shelf
                    SYNE1         cg02841912   \<0.0001   0.0051        −0.1408                                                       6     N_Shore
  UTR3Ind           PITPNB        cg26564117   \<0.0001   0.0117        −0.1436                                                       22    \-
  Intergenic        \-            cg15986587   \<0.0001   0.0159        −0.1789                                                       19    N_Shelf
                    \-            cg16349093   \<0.0001   0.0158        −0.1776                                                       5     \-
                    \-            cg21852792   \<0.0001   0.0171        −0.1654                                                       2     N_Shelf
                    \-            cg04075726   \<0.0001   0.0079        −0.1627                                                       2     \-
                    \-            cg26828017   \<0.0001   0.0192        −0.1584                                                       16    \-
                    \-            cg01861537   0.0001     0.0342        −0.1544                                                       11    \-
                    \-            cg09599062   \<0.0001   0.0050        −0.1521                                                       3     \-
                    \-            cg12475879   0.0002     0.0394        −0.1518                                                       17    S_Shelf
                    \-            cg01023672   0.0001     0.0383        −0.1461                                                       12    S_Shelf
                    \-            cg04697624   \<0.0001   0.0189        −0.1409                                                       12    N_Shelf

β-difference for the congenital hypopituitarism patients minus control. FDR, false discovery rate; Chr, chromosome.

###### 

Characteristics of the patients with congenital hypopituitarism and controls in the validation set.

  Characteristics          Congenital hypopituitarism, n=40   Controls, n=40        P-value
  ------------------------ ---------------------------------- --------------------- ----------
  Basic information                                                                 
   Age, years              26.49±3.42                         25.08±3.56            0.143
   Height, cm              166.7±8.71                         171.5±6.34            0.093
   Weight, kg              63.28±14.92                        65.31±7.06            0.068
   BMI, kg/m^2^            23.10±4.19                         22.23±2.31            0.768
  Thyroid function                                                                  
   FT3, pmol/l             3.77 (2.57-5.07)                   4.19 (2.32-5.43)      0.196
   FT4, pmol/l             11.28 (6.96-16.92)                 12.45 (7.34-17.08)    0.090
   TSH, *µ*IU/l            0.15 (0.00-4.42)                   1.53 (0.56-3.25)      \<0.001
  Corticotropic function                                                            
   Cortisol, *µ*g/dl       3.01 (0.13-19.13)                  13.69 (7.10-21.21)    \<0.001
   ACTH, pg/ml             20.54 (4.65-60.15)                 43.00 (20.00-55.00)   \<0.001
  Gonadotropic function                                                             
   LH, mIU/l               0.18 (0.01-3.98)                   3.82 (1.27-8.26)      \<0.0001
   FSH, *µ*IU/ml           0.72 (0.05-6.16)                   5.04 (1.45-10.36)     \<0.0001
   PRL, ng/ml              15.79 (1.63-54.57)                 8.32 (3.56-11.67)     \<0.0001
   E2, pg/ml               24.30 (20.00-68.90)                23.00 (20.00-45.40)   0.8898
   PROG, ng/ml             0.10 (0.10-0.49)                   0.10 (0.10-0.89)      0.1731
   TESTO, ng/ml            2.59 (0.10-10.67)                  4.31 (2.25-7.02)      0.0429

The data for basic information are presented as the mean ± standard deviation. All other data are presented as the median (range). ACTH, adrenocorticotropic hormone; BMI, body mass index; FT3, free thyroxine 3; FT4, free thyroxine 4; TSH, thyroid stimulating hormone; PRL, prolactin; PROG, progesterone; TESTO, testosterone; LH, luteinising hormone; FSH, follicle-stimulating hormone.
